Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01958203
Other study ID # 122012-11
Secondary ID
Status Completed
Phase N/A
First received September 29, 2013
Last updated October 8, 2013
Start date January 2013
Est. completion date September 2013

Study information

Verified date October 2013
Source Ministry of Health, United Arab Emirates
Contact n/a
Is FDA regulated No
Health authority United Arab Emirates: Ministry of Health
Study type Observational

Clinical Trial Summary

Study Title:Assessment of Adherence to Guidelines for Thromboprophylaxis in a Tertiary United Arab Emirates (UAE) hospital

Study Site: Al Qassimi Hospital, United Arab Emirates

Study Objectives:

The primary objective of this study is assessment of appropriateness of VTE prophylaxis administered to critically ill and surgical patients for whom pharmacologic treatment is indicated according to the American College of Chest Physicians (ACCP) 2012 guidelines.

The secondary objective is to:

1.Identify some causes of inadequate VTE prophylaxis in different patient populations, such as prescribing problems and errors at the level of administration.

Study Design: Cross sectional retrospective observational study

Sample size: Approximately 400

Study Population:

Inclusion criteria

Patients who meet the following criteria will be included:

1. Patients aged 18 and above.

2. Patients admitted to any of the critical care units, or the general or orthopaedic surgical wards.

3. Patients who have been in hospital more than 24 hours.

4. Caprini score > 1 (see procedure)

Exclusion criteria

Patients with any of the following criteria will be excluded:

1. Patients who have been admitted to a critical care unit and transferred out to a non surgical unit within 24 hours of admission.

2. Patients receiving oral anticoagulant therapy for indications other than VTE prophylaxis or treatment, such as atrial fibrillation and prosthetic heart valves.

Study Outcome Measurements:

The main outcome measure of interest is to determine the proportion of patients who have received inappropriate or inadequate VTE prophylaxis considering their calculated risk factor compared to the recommended prophylactic measures for that risk.

Secondary outcome measures are to identify whether there is inadequate VTE prophylaxis because of medication errors such as missed doses or wrong doses given.

Study Duration: 4 months

Statistical Analysis Data was entered into Microsoft Excel® and subsequently checked to ensure accurate data entry and correct any errors. It was subsequently exported into SPSS version 20 where it will be analysed.Quantitative data such as age was expressed mean (± standard deviation). Categorical data such as gender, risk factors for bleeding, type of mechanical and pharmacologic prophylaxis, missed doses and wrong doses were expressed as number and percentage of population.The student's t-test was used to analyse parametric data. The Pearson Chi-Square Test and Wilcoxon Rank sum test were used to analyse non parametric data. Simple and multiple logistic regression analysis was done to identify factors that are associated with inappropriate VTE prophylaxis. Factors that were included in the analysis included: age, type of admission (medical or surgical), area of admission (critical care, general surgery, orthopaedic surgery), Caprini score, and inappropriate VTE prophylaxis as the outcome. A p-value of less than 0.05 was be considered statistically significant.


Recruitment information / eligibility

Status Completed
Enrollment 386
Est. completion date September 2013
Est. primary completion date August 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patients aged 18 and above.

2. Patients admitted to any of the critical care units, or the general or orthopaedic surgical wards.

3. Patients who have been in hospital more than 24 hours.

4. Caprini score > 1 (see procedure)

Exclusion Criteria:

1. Patients who have been admitted to a critical care unit and transferred out to a non surgical unit within 24 hours of admission.

2. Patients receiving oral anticoagulant therapy for indications other than VTE prophylaxis or treatment, such as atrial fibrillation and prosthetic heart valves.

Study Design

Time Perspective: Retrospective


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Ministry of Health, United Arab Emirates

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients receiving inappropriate or inadequate VTE prophylaxis Case Report Form Analysis Form 2 weeks No
Secondary Number of patients receiving inadequate VTE prophylaxis due to medication errors, missed doses etc. Case Report Form Analysis Form 2 weeks No
See also
  Status Clinical Trial Phase
Recruiting NCT05347550 - Examining the Benefit of Graduated Compression Stockings in the Prevention of vEnous Thromboembolism in Low-risk Surgical Patients N/A
Enrolling by invitation NCT05794165 - Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism Phase 2
Completed NCT02379806 - The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study Phase 3
Recruiting NCT03691753 - Safety and Efficacy Study of Fitaya Vena Cava Filter N/A
Completed NCT02197416 - Safety of Dabigatran Etexilate in Blood Clot Prevention in Children Phase 3
Recruiting NCT05378035 - DOAC in Chinese Patients With Atrial Fibrillation
Recruiting NCT05171075 - A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Phase 3
Completed NCT01895777 - Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE) Phase 3
Completed NCT05897697 - Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
Completed NCT04736719 - Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
Completed NCT04735523 - Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
Completed NCT04736420 - Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
Completed NCT02829957 - RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding Phase 2/Phase 3
Completed NCT02746185 - Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban Phase 3
Completed NCT02912234 - Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants Phase 1
Completed NCT02334007 - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Phase 1/Phase 2
Completed NCT02223260 - Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age Phase 2
Completed NCT02661568 - Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES) N/A
Completed NCT01972243 - Risk of Recurrent Venous Thrombosis: A Validation Study of the Vienna Prediction Model
Completed NCT01431456 - Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery Phase 3